Reports Q3 revenue $1.81M vs $1.556M last year. Marvin Slosman, CEO of InspireMD (NSPR), commented: “Since our last quarterly update, we have made significant progress advancing our best-in-class carotid implant, CGuard Prime, towards potential U.S. approval while also moving toward the initiation of a pivotal study of CGuard Prime for a TCAR indication, which represents a key component of our commercial strategy.”
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on NSPR:
- NSPR Earnings Report this Week: Is It a Buy, Ahead of Earnings?
- InspireMD Expands with New Miami Headquarters
- InspireMD announces establishment of global headquarters in Florida
- InspireMD announces approval of IDE application for CGUARDIANS II study
- InspireMD Advances with FDA Study Approval and Global Goals